COMMUNIQUÉS West-GlobeNewswire

Major Shareholder Announcement
01/04/2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis [...]
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
01/04/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 16 March 2026 and in line with the company’s usual practice, the Board of [...]
AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure
01/04/2026
Durham, N.C., April 01, 2026 (GLOBE NEWSWIRE) -- Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopathy and New York [...]
ONWARD Medical Publishes Convocation of the 2026 Annual General Meeting of Shareholders and Proposed Resolutions
01/04/2026
EINDHOVEN, the Netherlands, April 01, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and [...]
Your Next Dental Appointment May Save Your Life
01/04/2026
Alberta Oral Health Professionals Urge Patients to Know the Signs of Oral Cancer EDMONTON, Alberta, March 31, 2026 (GLOBE NEWSWIRE) -- When you sit down for a routine dental visit, your oral health professional is doing [...]
Algernon Health Announces Proposed Name Change to “Grey Matters Health Inc.” and a 10:1 Share Consolidation
01/04/2026
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “ Company ” or “ Algernon ”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that it [...]
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
01/04/2026
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a [...]
FibroBiologics Announces Pricing of $3 Million Public Offering
01/04/2026
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
SpartaMax Claims Evaluated: Powerful Sparta Max Gummies for Maximum Performance Support in Men
01/04/2026
A 2026 informational overview of how the SpartaMax male enhancement gummy positions its Tongkat Ali, Ashwagandha, Maca Root, and Horny Goat Weed ingredient profile, individual dosage disclosures, formulation approach, [...]
Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
31/03/2026
Company outlines near-term pharmacokinetic milestones, highlights amorphous formulation strategy, and announces planned global patent filing TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ( [...]
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
31/03/2026
BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer [...]
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
31/03/2026
Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: [...]
Jushi Holdings Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
31/03/2026
Revenue of $262.9 Million for Full Year 2025, Up 2% Year-Over-Year, Reflecting Contributions from New Store Openings Operational Turnaround Advanced in 2025 with Meaningful Improvements in Cultivation Performance and [...]
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
31/03/2026
WESTLAKE VILLAGE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
31/03/2026
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway [...]
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
31/03/2026
– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session [...]
BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference
31/03/2026
POMPANO BEACH, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue [...]
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/03/2026
ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
31/03/2026
The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026 BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company [...]

Pages